TY - JOUR
T1 - A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)
AU - Martinon-Torres, Federico
AU - Wysocki, Jacek
AU - Szenborn, Leszek
AU - Carmona-Martinez, Alfonso
AU - Poder, Airi
AU - Dagan, Ron
AU - Richmond, Peter
AU - Gilbert, Christopher
AU - Trudel, Marie Chantale
AU - Flores, Sheryl
AU - Lupinacci, Robert
AU - McFetridge, Richard
AU - Wiedmann, Richard T.
AU - Chen, Qiuxu
AU - Gerrits, Han
AU - Banniettis, Natalie
AU - Musey, Luwy
AU - Bickham, Kara
AU - Kaminski, Janusz
N1 - Funding Information:
We would like to thank all of the participants, study staff, and investigators in the V114-025 (PNEU-PED-EU-1) study group for their invaluable contributions to this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by Elizabeth Haygreen, of Scion, London, and editorial support was provided by Ian Norton, of Scion, London according to Good Publication Practice guidelines ( Link ). This assistance was funded by Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. A full list of investigators for this study can be found in Supplementary Table S15 .
Funding Information:
We would like to thank all of the participants, study staff, and investigators in the V114-025 (PNEU-PED-EU-1) study group for their invaluable contributions to this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by Elizabeth Haygreen, of Scion, London, and editorial support was provided by Ian Norton, of Scion, London according to Good Publication Practice guidelines (Link). This assistance was funded by Merck Sharp & Dohme LLC. a subsidiary of Merck & Co. Inc. Rahway, NJ, USA. A full list of investigators for this study can be found in Supplementary Table S15. This study was funded by Merck Sharp & Dohme LLC. a subsidiary of Merck & Co. Inc. Rahway, NJ, USA. The data sharing policy, including restrictions, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc. Rahway, NJ, USA is available at https://engagezone.msd.com/ds_documentation.php through the EngageZone site or via email to [email protected].
Publisher Copyright:
© 2023
PY - 2023/5/16
Y1 - 2023/5/16
N2 - Background: V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa–HBV–IPV/Hib and rotavirus RV1 vaccines. Methods: V114 and PCV13 were administered in a 2+1 schedule at 2, 4, and 11–15 months of age. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series (PPS), immediately prior to a toddler dose, and 30 days post-toddler dose (PTD). Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for the two additional serotypes. Results: 1184 healthy infants 42–90 days of age were randomized 1:1 to V114 (n = 591) or PCV13 (n = 593). Proportions of participants with solicited AEs and serious AEs were comparable between vaccination groups. V114 met pre-specified non-inferiority criteria for all 13 shared serotypes, based on the difference in proportions of participants with serotype-specific IgG concentrations ≥0.35 μg/mL (response rate; lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5), and pre-specified superiority criteria for serotypes 22F and 33F (lower bound of two-sided 95% CI >10.0 for response rates and >2.0 for GMC ratios). Antibody responses to DTPa–HBV–IPV/Hib and RV1 vaccines met pre-specified non-inferiority criteria, based on antigen-specific response rates to DTPa–HBV–IPV/Hib and anti-rotavirus IgA geometric mean titers. Conclusions: After a 2+1 schedule, V114 elicited non-inferior immune responses to 13 shared serotypes and superior responses to the two additional serotypes compared with PCV13, with comparable safety profile. These results support the routine use of V114 in infants. Trial registration: ClinicalTrials.gov:
AB - Background: V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa–HBV–IPV/Hib and rotavirus RV1 vaccines. Methods: V114 and PCV13 were administered in a 2+1 schedule at 2, 4, and 11–15 months of age. Adverse events (AEs) were collected on Days 1–14 following each vaccination. Serotype-specific anti-pneumococcal immunoglobulin G (IgG) was measured 30 days post-primary series (PPS), immediately prior to a toddler dose, and 30 days post-toddler dose (PTD). Primary objectives included non-inferiority of V114 to PCV13 for 13 shared serotypes and superiority of V114 to PCV13 for the two additional serotypes. Results: 1184 healthy infants 42–90 days of age were randomized 1:1 to V114 (n = 591) or PCV13 (n = 593). Proportions of participants with solicited AEs and serious AEs were comparable between vaccination groups. V114 met pre-specified non-inferiority criteria for all 13 shared serotypes, based on the difference in proportions of participants with serotype-specific IgG concentrations ≥0.35 μg/mL (response rate; lower bound of two-sided 95% confidence interval [CI] >−10.0) and IgG geometric mean concentration (GMC) ratios (lower bound of two-sided 95% CI >0.5), and pre-specified superiority criteria for serotypes 22F and 33F (lower bound of two-sided 95% CI >10.0 for response rates and >2.0 for GMC ratios). Antibody responses to DTPa–HBV–IPV/Hib and RV1 vaccines met pre-specified non-inferiority criteria, based on antigen-specific response rates to DTPa–HBV–IPV/Hib and anti-rotavirus IgA geometric mean titers. Conclusions: After a 2+1 schedule, V114 elicited non-inferior immune responses to 13 shared serotypes and superior responses to the two additional serotypes compared with PCV13, with comparable safety profile. These results support the routine use of V114 in infants. Trial registration: ClinicalTrials.gov:
KW - Immunogenicity
KW - Pediatric
KW - Pneumococcal conjugate vaccine
KW - Pneumococcal disease
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85153608218&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.04.036
DO - 10.1016/j.vaccine.2023.04.036
M3 - Article
C2 - 37105892
AN - SCOPUS:85153608218
SN - 0264-410X
VL - 41
SP - 3387
EP - 3398
JO - Vaccine
JF - Vaccine
IS - 21
ER -
